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Abstract
Chlamydial infection is one of the most common sexually transmitted  
infections worldwide, showing no decreasing trends in the incidence the last years. 
As a result, it presents a major burden of disease that impacts negatively people’s 
sexual and reproductive health and may result in adverse perinatal outcomes. The 
aim of the chapter is to offer today’s practitioners trustworthy guidance on the latest 
data in chlamydial infection. Thorough, up-to-date content on the epidemiology, 
pathophysiology, risk factors, clinical manifestations, diagnosis, treatment, preven-
tion, prognosis and outcomes of infected infants, is presented. Data in children and 
adolescents that differ from infants, are also discussed. The chapter is organized 
consistently in order to help readers find information quickly and easily and thus, 
provide direct, optimal and evidence-based care to every pediatric patient.
Keywords: Chlamydia trachomatis, chlamydial infection, conjunctivitis, pneumonia, 
infant, children, adolescents
1. Introduction
More than 1 million sexually transmitted infections are acquired every day 
worldwide and chlamydial infection is the most common in the developed world, 
showing no decreasing trends in the incidence the last years [1]. As a result, chla-
mydial infection presents a major burden of disease that impacts negatively people’s 
sexual and reproductive health and may result in adverse perinatal outcomes. As 
chlamydiae are largely asymptomatic and high rates of antibiotic resistance [2] have 
been shown, screening and treatment are the most crucial issues to reduce their 
impact globally.
Chlamydial infection can be transmitted to the infant during childbirth, result-
ing in conjunctivitis or pneumonia as a clinical disease. If present beyond the 
neonatal period in a child, may be a sign of sexual abuse. Sexually transmitted 
infection can occur in sexually active adolescents leading to a cascade of potentially 
serious inflammatory-induced sequelae.
2. Definition - background
“Chlamydiae”, originate from the Greek word “chlamyda”, meaning “cloak”. 
They are Gram-negative obligate intracellular bacteria pathogenic to humans 
or animals and mainly transmitted through direct contact with infected tissue, 
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including vaginal, anal or oral sex and can even be passed from an infected mother 
to the newborn during childbirth. Some species though, pathogenic to animals can 
be transmitted to humans also [3].
Chlamydiae have a unique biphasic developmental cycle which involves tran-
sition between two major morphologic forms: (1) the infectious forms, called 
elementary bodies convert into (2) non-infectious, reproductive forms, called 
reticulate bodies. This transition takes place within the host cell and differentiates 
the metabolically inactive elementary body into the metabolically active reticulate 
body. The reticulate body contains no cell wall and is detected as an inclusion in the 
cell. Chlamydiae contain DNA, RNA and ribosomes [4, 5].
There are four recognized species of Chlamydiae: Chlamydia trachomatis, 
Chlamydia psittaci, Chlamydia pneumoniae, and Chlamydia pecorum. Humans are 
the only natural host for Chlamydia trachomatis (C. trachomatis). This bacterium has 
a distinct developmental cycle, approximately 48–72 hours, which only replicates 
inside eukaryotic host cells. It uses energy phosphate compounds from the host 
cell during its growth and replication [6]. Preferentially infects squamo-columnar 
epithelial cells of the eye and the genital tract. Its genome size is 1000 kB [7].
3. Pathophysiology
Although infection by C. trachomatis is a major sexually transmitted genital 
infection globally, eye infections may be also spread by personal contact and 
contaminated items which are touched or held by hands, such as towels, in areas 
with poor sanitation [8]. Repeated and chronic infections, usually in developing 
countries, can lead to trachoma, which is a chronic follicular keratoconjunctivitis 
that causes scarring and neovascularization of the cornea that can result in 
blindness [9].
In women, genital tract infections with by C. trachomatis are usually asymptom-
atic and that is why it is frequently characterized as the “silent epidemic” [10]. If left 
untreated though, it can lead to serious sequelae, including urethritis, bartholinitis, 
mucopurulent cervicitis, endometritis, salpigitis, and pelvic inflammatory disease 
which may subsequently compromise fertility or predispose to ectopic pregnancy. 
Additionally, several pregnancy complications have been linked to chlamydial 
infection, including chorioamnionitis, premature rupture of membranes, preterm 
labour and birth, low birth weight, intrauterine growth restriction and postpartum 
endometritis [11–15]. In males, (or men) may cause epididymitis, proctitis, prosta-
titis, urethritis and reactive arthritis [16].
In infants, C. trachomatis can cause conjunctivitis and/or pneumonia. More 
rarely, C. trachomatis occurs also in the vagina, urethra and rectum. Occasional C. 
trachomatis infection in children and adolescents (with no prior sexual activity) 
should be seen in the context of sexual abuse, especially when Chlamydiae are 
detected in the anorectal or genital region [17].
There are 18 serotypes of C. trachomatis. The genital strains belong to one of the 
serotypes D through K while trachoma strains to the serotypes A through C [18]. 
The most common genotype among infants is type E [19, 20].
4.  Prevalence
Based on prevalence data from 2009 to 2016, the estimated pooled global preva-




3.8% and 2.7%, respectively [21]. Rates of infection among adolescent girls exceed 
20% in many urban populations, but can be as high as 15% in suburban popula-
tions [22].
Worldwide, the prevalence of C. trachomatis in pregnant women varies from 
1.0%–36.8%, while in high income countries it is estimated from 3%–14% [23]. 
Especially in European western countries, the prevalence of genital C. trachomatis 
infection in pregnant women based on nucleic acid amplification tests (NAAT) 
from either first void urine or a vaginal and/or endocervical swab, ranges from 3% 
to 6% [24]. However, prevalence may vary significantly during pregnancy among 
different continents [23] (Figure 1).
Approximately 50%–70% of infants exposed to an infected mother’s genital 
flora during vaginal birth, will acquire chlamydia infection if no prophylaxis is 
given before or just after birth. More specifically, the 10%–20% of all infected 
infants will develop pneumonia and the 30%–50% conjunctivitis. Prevalence data 
of neonatal chlamydial conjunctivitis and pneumonia from several regions [25] are 
summarized in Figure 2.
Figure 1. 
Prevalence of C. trachomatis infection in pregnant women across all continents.
Figure 2. 




It seems that young women (<25 years old) are more prone to chlamydial infec-
tion due to anatomic differences in the cervix, such as cervical ectropion [16, 26]. 
In this condition, the glandular cells that line the endocervix are present on the 
ectocervix, leading to exposure of the glandular cells to the vaginal milieu and C. 
trachomatis has a preference for the glandular epithelium [5, 27].
Other factors associated with an increased risk of infection are numerous 
sexual partners, sexual intercourse with non-condom use, absence of barrier 
contraceptives, use of oral contraceptives, partner with concurrent partners or 
sexually-transmitted disease or non-gonococcal urethritis, non-gonococcal muco-
purulent cervititis, sterile pyuria, other sexually transmitted diseases, unmarried 
status, nulliparity, African/American/Hispanic ethnicity and poor socio-economic 
condition [5, 23, 28].
Regarding infants, the main risk factor is vertical transmission (mother-to-
child) after vaginal birth. Transmission after a cesarean section is unusual, unless 
premature rupture of the membranes of an infected mother is reported.
6. Clinical presentation
6.1 Conjunctivitis
Neonates exposed to C. trachomatis in an infected birth canal may develop 
conjunctivitis, sometimes referred to as “ophthalmia neonatorum”, with transmis-
sion rate from 30%–50% [25]. Neonatal conjunctivitis caused by C. trachomatis 
has been reported as the most common infectious cause of neonatal conjunctivitis 
worldwide.
Conjunctivitis typically occurs between 5–14 days after delivery and can be 
unilateral or bilateral. It has a variety of clinical presentations in the infant. It is 
characterized by palpebral erythema and oedema, as well as eye discharge. Initially, 
the eye discharge is watery and later becomes purulent and copious. Moderate eye 
drainage and redness is common. Corneal opacification, chemosis and pseudomem-
branes may be present. Topical prophylaxis with erythromycin does not prevent but 
reduces the incidence of the chlamydial conjunctivitis [29–31].
Moreover, the 10%–20% of the infants with chlamydial conjunctivitis will 
develop pneumonia [25].
6.2 Pneumonia
The species C. psittaci, C. trachomatis and C. pneumoniae can all cause pneu-
monia in humans. Perinatal transmission of C. trachomatis has been reported to 
cause neonatal pneumonia with potentially a life-threatening severity. Usual age 
of presentation is at 3 weeks to 3 months of life [32]. In half of the cases concur-
rent or previous conjunctivitis is present and in one third of the cases otitis media 
is co-existing [33]. When C. pneumoniae is the cause, infection is predominantly 
asymptomatic or mild but can result in the development of acute upper and lower 
respiratory illness [34].
Upper and lower respiratory tracts may be directly infected intrapartum. 
C. trachomatis, which is the most common though, has been documented to be 
pathogen causing lower respiratory tract infection in children less than 6 months 
of age. Infants may present moderate symptoms, such as rhinitis, mucoid rhinor-




pneumonia. Most cases are afebrile. When pneumonia occurs, tachypnea, nasal 
obstruction and/or discharge, interstitial and peribronchiolar inflammation may 
exist, leading to significant morbidity manifested as low grade fever and parox-
ysmal staccato cough. Crepitant inspiratory rales often are heard on auscultation 
of the lungs, in contrast with expiratory wheezes which are distinctly uncommon. 
Hyperinflation of the lungs usually accompanies the diffused infiltrates observed 
on chest X-rays. Reticulonodular patterns and atelectasis have also been described. 
Eosinophilia may be also present [33, 35, 36].
In premature infants chlamydial pneumonia can be more serious. In the begin-
ning, respiratory distress is observed which is followed later by worsening respira-
tory signs [37]. Apnea spells and respiratory failure may present as well [33, 38]. If 
chlamydial pneumonia is left untreated, infants are at high risk of developing later 
pulmonary dysfunction and possibly chronic respiratory disease, including mild to 
severe asthma [36]. Prophylaxis does not eliminate nasopharyngeal colonization or 
pneumonia.
It should be taken into consideration that C. trachomatis and C. pneumoniae 
are agents associated with community-acquired pneumonia in children and ado-
lescents. They have not been associated with specific clinical syndromes among 
children and adolescents. Nevertheless, pharyngitis, bronchitis, and sinusitis may 
be present [38, 39].
6.3 Other clinical presentations in children and adolescents
In prepubertal girls, vaginitis may present, while in postpubertal girls, ure-
thritis, bartholinitis, cervicitis, endometritis, salpingitis, proctitis, perihepatitis, 
are possible manifestations of the disease. Long-lasting infections may result in 
ectopic pregnancy, infertility or pelvic inflammatory disease [11, 13, 35]. In males, 
chlamydial infection may cause epididymitis, proctitis, prostatitis, urethritis and 
reactive arthritis. Lymphogranuloma venereum is extremely rare in children and 
adolescents below the age of 18 years old and is usually confined to HIV positive 
and homosexual men [35, 40].
Repeated and chronic chlamydial infection that affects eyes can lead to 
trachoma, a chronic follicular keratoconjunctivitis that causes scarring and neo-
vascularization of the cornea and can even result in irreversible blindness [9]. It 
can be spread through contact with the eyes, eyelids, nose or throat secretions of 
infected people. Chlamydiae can be transmitted by contaminated handkerchiefs, 
towels, clothes or bed linen as well. Signs and symptoms of trachoma usually affect 
both eyes and may include: mild itching and irritation of the eyes and eyelids, eye 
discharge containing mucus or pus, eyelid swelling, light sensitivity (photophobia), 
eye pain, eye redness and vision loss. In areas where trachoma is endemic, usually 
poor and rural, active (inflammatory) trachoma is common among preschool-aged 




For conjunctival specimens, any purulent exudate should be removed before 
collecting epithelial cells by rubbing a dry swab over the everted palpebral con-
junctiva. The conjunctivae are often friable and may bleed after swabbing so great 
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attention is needed. For suspected pneumonia, material should be obtained from 
nasopharyngeal aspiration or deep suctioning of the trachea.
Culture of the bacterium is considered as the gold standard for diagnosing neo-
natal conjunctivitis and pneumonia. Proficiency in specimen collection and trans-
port is paramount to accuracy in diagnostic testing for Chlamydiae [5, 42]. Both the 
sensitivity and the specificity of culture is nearly 100% but is directly related to the 
adequacy of the specimen. For optimal isolation of the bacteria, specimens should 
be refrigerated immediately after collection at 2 to 8 °C and kept at this temperature 
during transport to the laboratory. The intervening period between collection and 
laboratory processing of specimens should ideally not exceed the 48 hours [42].
7.1.2 Nucleic acid amplification test (NAAT)
This method amplifies the nucleic acid sequences of chlamydiae. Non-viable 
bacteria can be detected contrary to cell culture. All relevant clinical materials 
can be analyzed by NAATs, including urethral, cervical, vulvo-vaginal, anorectal 
and ocular swabs, first void urine, sperm or tissues [43]. The test is recom-
mended for routine use in adults and older children but data relating to infants 
are insufficient. The NAATs have not been approved by the US Food and Drug 
Administration (FDA) for testing of conjunctival specimens from infants with 
suspected C. trachomatis conjunctivitis or for testing of nasopharyngeal swab, 
tracheal aspirate or lung biopsy specimens from infants with suspected C. tracho-
matis pneumonia [33, 35].
7.1.3 Antigen detection tests
Antigen tests based on the detection of either chlamydial lipopolysaccharides 
(enzyme immunoassay, EIA) or direct fluorescent antibodies (DFA) have also 
been found to perform relatively well when used with conjunctival specimens. 
Sensitivity of nasopharyngeal samples is poor. Antigen tests are no longer 
recommended for chlamydia testing in infants due to insufficient diagnostic 
accuracy [43].
7.1.4 Serum anti-chlamydial antibody concentration
Chlamydial IgG antibodies detected from infants during the first months of life 
reflect maternally transferred antibodies and correlate with the levels of maternal 
serum antibodies. Maternal IgG antibodies do not protect infants from developing 
chlamydial infection and infants born to antibody positive mothers usually lose 
their maternally transferred IgG-antibodies by nine months of age [24]. In infants 
with chlamydial pneumonia a microimmunofluorescence serum titer of ≥1:32 is 
considered diagnostic for infection [31, 33]. The IgM antibodies have been observed 
to develop as early as five days after infection and to persist for three months. Their 
determination is difficult and availability limited [24].
7.1.5 Other tests
Obtaining lung biopsies is not a routine practise for confirming chlamydial 
pneumonia, since the course of the disease is rarely fatal, but when a biopsy is 
obtained the material should be examined for chlamydiae [44]. Additionally  
in pneumonia, eosinophilia in the peripheral blood is usual with white blood cell 
count being normal. Blood gas measurements reveal mild to moderate  





In cases of chlamydial pneumonia, the most chest radiographs show bilateral 
hyperexpansion and diffuse infiltrates with a variety of radiographic patterns, includ-
ing interstitial, reticular nodular, atelectasis, coalescence and bronchopneumonia. 
Pleural effusion and lobar consolidates are usually absent [33, 45]. Radiological 
findings alone are non-specific so it is almost impossible to determine by radiographic 
manifestations that a specie of clamydiae is the causative organism of the pneumonia.
8. Treatment
8.1 Conjunctivitis
Oral erythromycin base or ethylsuccinate is a usual treatment for conjunctivitis 
in the infant, although erythromycin has been reported as risk factor for infantile 
hypertrophic pyloric stenosis when administered the first 2 weeks of life. Thus, 
parents and physicians should observe infants closely for any signs of intestinal 
obstruction. Azithromycin is an acceptable alternative [30, 33, 35] which is also 
recommended by WHO in neonates with chlamydial conjunctivitis [46]. Dosages in 
the most preferable treatments are:
• Oral erythromycin 50 mg/kg/day in 4 divided doses for 14 days or
• Oral azithromycin 20 mg/kg/day for 3 days
8.2 Pneumonia
For children, the following regimens can be used for respiratory infection  
due to C. trachomatis and C. pneumoniae [47]:
Preferred therapy intravenously
• azithromycin 10 mg/kg on days 1 and 2 of therapy; transition to oral therapy 
if possible
Accepted alternatives are:
• erythromycin lactobionate 20 mg/kg/day every 6 hours
• levofloxacin 16–20 mg/kg/day in 2 doses for children 6 months to 5 years old 
and 8–10 mg/kg/day once daily for children 5 to 16 years old; maximum daily 
dose should not exceed the 750 mg
Preferred therapy orally [47, 48].
• azithromycin 10 mg/kg/once on day 1, followed by 5 mg/kg/day once daily for 
2–5 days
Accepted alternatives are:
• clarithromycin 15 mg/kg/day for 10 days
• erythromycin 50 mg/kg/day for 10–14 days
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• doxycycline 2–4 mg/kg/day in 2 doses for children with age greater than 
7 years old
• levofloxacin 500 mg once daily or moxifloxacin 400 mg once daily for adoles-
cents with skeletal maturity
Antibiotic resistance may diminish the overall efficacy of antibiotics, thus, it is 
strongly advised to follow-up patients to determine whether initial treatment was 
effective [33, 35, 39]. Clarithromycin is therapeutically equivalent to other antibiot-
ics studied and is associated with a better bacteriological eradication and a lower 
risk for related adverse events in children [49]. In general, no isolation measures 
are necessary. Parents or mother and her sexual partner should be evaluated and 
treated if needed.
8.3 Uncomplicated genital chlamydial infection
For adolescents with uncomplicated genital chlamydial infection, guidelines 
relating to sexually transmitted diseases by WHO [46] suggest one of the following 
options:
• oral azithromycin 1 g as a single dose
• oral doxycycline 100 mg twice a day for 7 days
or one of the following alternatives:
• oral tetracycline 500 mg four times a day for 7 days
• oral erythromycin 500 mg twice a day for 7 days
• oral ofloxacin 200–400 mg twice a day for 7 days
Children with body weight < 45 kg, the recommended regimen is [35]:
• oral erythromycin base or ethylsuccinate, 50 mg/kg/day, divided into 4 doses 
daily for 14 days.
Children with body weight > 45 kg and age < 8 years old, the recommended 
regimen is [35]:
• oral azithromycin 1 g in a single dose
For children 8 years old and older, the recommended regimens are [35]:
• oral azithromycin 1 g in a single dose or
• oral doxycycline 100 mg twice a day for 7 days
8.4 Lymphogranuloma venereum (LGV)
In adolescents with LGV, it is suggested by WHO [46] the administration of 






The most effective method of controlling perinatal chlamydial infection appears 
to be screening and treatment of pregnant women. The U.S. Centers for Disease 
Control and Prevention (CDC) recommend that “all pregnant women aged <25 
years and older women at increased risk for infection should be routinely screened 
for C. trachomatis at the first prenatal visit and be retested during the third trimes-
ter to prevent maternal postnatal complications and chlamydial infection in the 
neonate” [44]. Healthcare professionals must cooperate closely to identify early the 
high-risk populations, educate and counsel the patients about sexual health and 
importance of screening and completing treatment.
According to recommendation of WHO [46], all neonates should be offered 
immediately after birth topical ocular prophylaxis to both eyes for the prevention 
of gonococcal and chlamydial ophthalmia neonatorum with one of the following 
options:
• tetracycline hydrochloride 1% eye ointment
• erythromycin 0.5% eye ointment
• povidone iodine 2.5% solution (water-based)
• silver nitrate 1% solution
• chloramphenicol 1% eye ointment
No vaccine is currently available for either trachoma or chlamydial genital infec-
tions. However, a first-in-human, randomized, double-blind, placebo-controlled, 
phase 1 trial was conducted between 2016–2017 to assess safety and immunogenic-
ity of a chlamydial vaccine candidate [50].
As far as trachoma is concerned, a WHO-recommended elimination strategy 
summarized by the acronym“SAFE”, is being implemented in endemic countries 
[41]. This consists of:
Surgery to treat the blinding stage.




If proper treatment starts early, chlamydial infection should resolve without 
complications and with good prognosis, overall. Patients with mild symptoms 
usually recover within 7–10 days after initiation of the treatment. Dry cough and 
general weakness can persist after the disease, slowing complete remission from 
1 week to 2 months. If neglected, serious complications may develop which can even 
lead to mortality [36].
11. Conclusion
Chlamydial infection is a significant worldwide public health problem, affect-
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high risk populations, with defined strategies, will eliminate crucially the burden 
of chlamydial infection. Obstetricians, gynecologists, midwives and pediatricians/
neonatologists should be educated up-to-date and offered trustworthy guidance on 
the latest data in chlamydial infection. By applying scientific knowledge in clinical 
practice, these professionals can provide direct, optimal and evidence-based care to 
every pediatric patient.
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